CEBPA^bi AML is uniformly sensitive to JAK inhibitors. (A) Volcano plot showing the comparative sensitivity of CEBPA^bi AML (n = 14) vs CEBPA^wt NK AML (n = 14) to selected small molecules. Dashed red line corresponds to P = .05. (B-D) Mean dose-response curves with SEM and IC₅₀-associated statistics comparing CEBPA^bi AML (n = 14) to CEBPA^wt NK AML (n = 14) for selected compounds as follows: (B) daunorubicin, (C) sorafenib, and (D) ruxolitinib and CYT387. Results for other compounds are shown in supplemental Figure 4. (E) IC₅₀ for ruxolitinib in all samples (n = 28) (left), CEBPA^bi GEP− AML (n = 3) and CEBPA^bi GEP+ AML (n = 11) (middle), and NK AML (n = 14) (right). CSF3R T618 mutated samples are indicated in orange. Horizontal bars represent medians. (F) Individual dose-response curves (gray) for GEP+ and GEP− (black, red, and blue curves) CEBPA^bi AML. Results for other JAK inhibitors are shown in supplemental Figure 6. (G) Mean dose-response curves with SEM and IC₅₀-associated statistics comparing CEBPA^bi GEP+ AML (n = 11) to CEBPA^wt NK AML (n = 14) for selected JAK inhibitors. Results for other JAK inhibitors are shown in supplemental Figure 7. P values were calculated using a Wilcoxon rank-sum test on IC₅₀ values. NS, not significant; SEM, standard error of the mean.